CDC advises healthcare providers on new tools to combat RSV
The CDC predicts increased activity of Respiratory Syncytial Virus (RSV) for the upcoming winter season, urging clinicians to implement new prevention tools like nirsevimab and FDA-approved vaccines for vulnerable populations. The advisory comes as RSV activity shows a changing pattern, affecting infants, children, and adults, and causing thousands of hospitalizations annually.